Kornimate/medical-research-clean huggingface dataset:
influence of thyroid hormones on the woundhealing process

Conditions: Thyroid Neoplasms; Thyroid Carcinoma

Summary: main goal of this clinical investigation is to investigate different cytokines in wound fluids of euthyroid vs. hypothyroid patients. as a primary endpoint we want to evaluate if different cytokine levels in euthyroid vs. hypothyroid patients exist and to what extent these cytokines differ. our targeted cytokines are: il6, il10, tnfa and mcp-1. from the literature these 4 factors seem to be the most reasonable to measure and to focus on. additionally we focus on these 4 factors for financial reasons, technically there wouldn't be a problem to measure more, which is correlated with higher costs. besides, more than 6 factors would mean larger amounts of sample fluids needed, which would cause technical problems. these factors don't have to change in the same direction. secondarily, we believe that differences in cytokine profiles of hypothyroidism vs. euthyroidism will correlate to differences in duration and clinical characteristics of the wound healing process.


Eligibility criteria:
inclusion criteria: * near total or total thyroidectomy because of struma multinodsa (nodular goiter) with or without substitution of thyroid hormone after operation * total thyroidectomy because of papillary carcinoma of thyroid gland (t1/t2 carcinoma, n1, m0) with planned radio-ablative therapy (rat) without or with rhtsh exclusion criteria: * pat\< 18 years * immune disease of thyroid gland (graves disease) * severe immunodeficiency * immunosuppressive medication because of solid organ transplantation * hepatitis a/b/c or hiv * all exclusion criteria for any surgical procedure
three types of nucleotide/nucleoside analogues treatment in hbv related aclf

Conditions: Hepatitis B; Acute-On-Chronic Liver Failure

Summary: this study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of hbv-related acute-on-chronic liver failure.

hepatitis b virus (hbv) related acute-on-chronic liver failure (aclf) is a serious condition with high mortality rate in china. nucleotide/nucleoside analogues are used for anti-virus treatment in these patients. entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide are first line drug in china. but there still lacks of data of tenofovir alafenamide in treatment of hbv related aclf. this study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of hbv related aclf.

Eligibility criteria:
inclusion criteria: 1. positive hepatitis b surface antigen or hepatitis b virus dna \> 0.5 year; 2. age from 12 to 65 years old; 3. serum total bilirubin level \> 10 times upper limit of normal; 4. prothrombin time activity \ 1.5； 5. do not receive nucleotide/nucleoside analogues treatment in the past half year. exclusion criteria: 1. other active liver diseases; 2. hepatocellular carcinoma or other malignancy; 3. pregnancy or lactation; 4. human immunodeficiency virus infection or congenital immune deficiency diseases; 5. severe diabetes, autoimmune diseases; 6. other important organ dysfunctions; 7. using glucocorticoid; 8. patients can not follow-up; 9. investigator considering inappropriate.

Keywords: hepatitis b virus acute-on-chronic liver failure nucleotide nucleoside
clinical efficacy of luna emg robot therapy for patients after stroke

Conditions: Stroke

Summary: a lot of studies prove that rehabilitation with the use of modern devices accelerates the recovery of function in patients after stroke. repeated correct movement patterns affect the central nervous system and stimulating its plasticity. despite the fact that so many studies confirm the validity of therapy using robots, it is still difficult to assess to what extent its use improves the effectiveness of traditional therapy. in these studies, we want to objectively assess the effectiveness of the luna device using emg biofeedback.


Eligibility criteria:
inclusion criteria: * patients over 6 months after stroke, * tibialis anterior strength (lovett scale) not less than 1 and not greater than 3, * ashworth scale in tibialis anterior 0,1, 2 exclusion criteria: * patients less than 6 months after stroke, * tibialis anterior strength (lovett scale) 0, 4, 5, * ashworth scale in tibialis anterior higher than 2, * damage to the central nervous system which is another incident, * serious cognitive deficit, * stiffness of the ankle.

Keywords: luna emg drop foot chronic stroke
physiological, cognitive, and personal features in the link between placebo-effect and variability of pain reports

Conditions: Chronic Back Pain

Summary: this study attempt to identify whether and how factors known or considered to be related with analgesic placebo effect or variability of pain reports separately, may contribute to their coupling. among these factors - personal traits such as optimism, focus of attention, suggestibility, and short-term memory along with characteristics of stress and relaxation. additionally, the role of pain sensitivity and the individual's pain modulation profile in the relationship between analgesic placebo effect and variability of pain reports will be examined.

data will be collected from 130 patients with non-specific chronic back pain that will be recruited for a prospective cross-sectional study. to characterize the main study variables, the participants will undergo the focused analgesia selection test (fast) which evaluates within-subjects variability of pain reports, and placebo manipulation containing administration of an inert injection accompanied by a verbal suggestion, which is expected to produce placebo effects. the involvement of additional factors considered associated with the within-subjects variability of pain reports and the placebo response will be explored. stress and well-being characteristics will be examined by measuring cortisol levels in saliva and in hair, salivary level of secretory immune globulin a (siga), and an autonomic nervous system function and a stress perception questionnaire. personal traits such as suggestibility, optimism, and focus of attention, will be examined using questionnaires. memory will be assessed by memory task, and factors related to the pain modulation system will be examined using psychophysical tests, and a pain sensitivity questionnaire.

Eligibility criteria:
inclusion criteria: * literate adults * aged 18 - 80 years * a diagnosis of chronic back pain * sufferings from back pain during the last 3 months or more, with an intensity of 3 or more on a 0-10 nrs exclusion criteria: * mental retardation or cognitive impairment * pregnancy or breast-feeding * malignancy and a diagnosis of malignant disease
addition of cisplatin to neoadjuvant therapy for t locally advanced breast cancer

Conditions: Tubular Breast Cancer; Mucinous Breast Cancer; Invasive Ductal Breast Cancer; Inflammatory Breast Cancer

Summary: the investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.

in this trial, all the patients will have weekly paclitaxel and cisplatin as neoadjuvant chemotherapy for 4 cycles. patients with her2 positive tumor will also receive the trastuzumab.

Eligibility criteria:
inclusion criteria: 1. women aged ≥18years and ≤70 years 2. at least on measurable disease according to the response evaluation criteria in solid tumors (recist). histologically confirmed invasive breast cancer, tumor size ≥2 cm, t2-4 n0-2m0 3. er/pr/her-2 and ki-67 status detected on core biopsy. er/pr positive is defined as \>1% stained cells and her2-positive is defined as immuno-histochemistry (ihc) 3+ or fish ratio ≥ 2.0 4. no prior systemic or loco-regional treatment of breast cancer 5. ecog 0-2 6. adequate bone marrow function:wbc≥4.0×109/l, absolute neutrophil count（anc）≥1.5×109/l, platelets（plt）≥100×109/l, hemoglobin（hb）≥90g/l;aspartate aminotransferase(ast),alanine aminotransferase (alt)≤1.5 upper normal limit （unl）, creatinine≤1.5 unl, bilirubin≤1.5unl 7. no obvious main organs dysfunction exclusion criteria: 1. unwilling or unable to use an acceptable method of contraception in 8 weeks (including 8 weeks) after final dose of test drug 2. patient is pregnant or breast feeding 3. inflammatory breast cancer and metastatic breast cancer 4. any evidence of sense or motor nerve disorders 5. patients with medical conditions taht indicate intolerant to neoadjuvant therapy, including uncontrolled cardiovascular disease, severe infection 6. any concurrent malignancy other than breast cancer 7. know severe hypersensitivity to any drugs in this study
vitamin d supplementation in patients with covid-19

Conditions: COVID-19

Summary: coronavirus disease 2019 (covid-19) was declared an emergency public health problem by the world health organization (who) in march 2020. since then, several initiatives by the medical and scientific community have sought alternatives to treat infected individuals, as well as identifying risk or protective factors for the contamination and prognosis of patients. in this perspective, vitamin d supplementation can improve some important outcomes in critically ill patients, being considered a potent immunomodulatory agent. vitamin d deficiency is a common outcome in critically ill patients, thus making it a modifiable risk factor with great potential for reducing hospital stay and intensive care and mortality. the investigators speculate that vitamin d supplementation could have therapeutic effects in patients with covid-19.


Eligibility criteria:
inclusion criteria: * diagnosis of flu syndrome with hospitalization criteria; * respiratory rate ≥ 24irpm and / or saturation \<93% in room air, or belonging to the risk group for complications: 1. chronic diseases: heart disease, diabetes mellitus, systemic arterial hypertension and neoplasms, 2. immunosuppression, 3. pulmonary tuberculosis; 4. obesity; * tomographic findings compatible with coronavirus disease. exclusion criteria: * patient admitted already under invasive mechanical ventilation; * patient admitted with severe acute respiratory syndrome and diagnosed with an etiologic agent other than sars-cov-2; * prior vitamin d supplementation (above 1000 iu/day); * renal failure requiring dialysis or creatinine ≥ 2.0mg/dl; * admitted patients with expected hospital discharge in less than 24 hours; * patient unable to sign the consent form.

Keywords: covid-19 vitamin d acute respiratory syndrome
treatment with romosozumab versus denosumab to improve bone mineral density and architecture in subacute sci

Conditions: Osteoporosis; Spinal Cord Injuries

Summary: the objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute sci compared to 24 months of denosumab administration alone.


Eligibility criteria:
inclusion criteria: 1. traumatic motor-complete or incomplete sci c4-l2 (ais grade a-c); 2. duration of sci less than 6 months; 3. males and females (premenopausal) between the ages of 18 and 55 years old; and a safe range of bmd right above the knee as determined by study staff review; exclusion criteria: 1. active and/or history of coronary heart disease or stroke; 2. bone cancer; 3. long-bone fracture of the leg within the past year; 4. history of prior bone disease (for example, paget's hyperparathyroidism, osteoporosis, etc.); 5. postmenopausal women; 6. men with known low functioning tests before sci; 7. drugs geared toward increasing bmd longer than a six month duration after sci; 8. as determined by study staff review of my medication history of glucocorticoid administration longer than three months duration within the last year 9. abnormalities of my endocrine glands such as hyperthyroidism, cushing's disease or syndrome, etc.; 10. severe underlying chronic disease (for example chronic obstructive pulmonary disease (copd), end-stage heart disease, chronic renal failure); 11. heterotopic ossification (ho) of the distal femur (the knee end of the thigh bone). ho is a condition where bone tissue forms outside of the skeleton. if ho is found in any other area than the distal femur it will not prevent my participation in the study.; 12. history of chronic alcohol abuse; 13. diagnosis of hypercalcemia (high levels of calcium in the blood); 14. pregnancy; 15. as determined by study staff review of my medications a bisphosphonate for heterotopic ossification (ho), or other medications to treat osteoporosis other than calcium and vitamin d; 16. current diagnosis of cancer or history of cancer; 17. as determined by study staff review of my medications, prescribed moderate or high dose corticosteroids (\>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute sci; and 18. life expectancy less than 5 years.

Keywords: osteoporosis spinal cord injuries dual energy x-ray absorptiometry denosumab romosozumab
clinical application of 99mtc-fdph46 spect/ct imaging in malignant solid tumor: a prospective exploratory study

Conditions: Malignant Tumors; Solid Tumor Malignancy

Summary: the goal of this observational study aims to preliminarily evaluate the diagnostic efficacy of 99mtc-fdph46 spect/ct in malignant solid tumors (compared to the pathological gold standard). the main questions it aims to answer are: * what is the diagnostic efficacy of 99mtc-fdph46 in malignant solid tumors, compared to the pathological gold standard? * what is the biodistribution, tumor uptake and safety of 99mtc-fdph46 spect/ct in patients with malignant solid tumors? participant will: • patients with clinically suspected or diagnosed malignant solid tumors who are willing to undergo 99mtc-fdph46 spect/ct examination and sign an informed consent form.

patients who are clinically assessed as suspected or diagnosed with malignant solid tumors will receive an intravenous injection of 20-25mci of 99mtc-fdph46. whole-body planar scintigraphy will be performed at 10, 30, 90, 150, and 240 minutes post-injection to obtain dynamic biodistribution images. additionally, 99mtc-fdph46 spect/ct imaging will be conducted 60-90 minutes after the intravenous injection to acquire both whole-body planar scintigraphy and spect/ct tomographic fusion images. after the scans are completed, patients will be observed in the waiting room for 1 hour before they are allowed to return.during the follow-up visit after the examination, the researchers will collect the patients' clinical information and any changes in symptoms, and record them in the medical records. all subjects will be followed up once on the same day after the spect/ct scan and again one week later.

Eligibility criteria:
inclusion criteria: 1. patients who are clinically suspected or diagnosed with malignant solid tumors. 2. ages between 18 to 80 years old. 3. stable vital signs, ecog score of 0-2, capable of tolerating and cooperating with the 99mtc-fdph46 spect/ct examination. 4. subjects who are willing to undergo the 99mtc-fdph46 spect/ct examination and have signed the informed consent form. exclusion criteria: 1. those who can not understand, comply with the research protocol or are unable to sign the informed consent form. 2. contraindications for spect imaging (including pregnant women, nursing women, women of childbearing age with recent plans to conceive, etc.). 3. unstable vital signs, ecog score \>2, unable to tolerate or cooperate with the 99mtc-fdph46 spect/ct examination process.

Keywords: 99mtc fdph46 spect malignant solid tumor
high versus low blood-pressure target in the post operative care of liver transplantation a randomized, controled, open and unicentric trial.

Conditions: Liver Transplant; Complications

Summary: liver pam a randomized, controled, open and unicentric trial comparing high (map 85-90 mmhg) and low (65-70 mmhg) target of mean arterial pressure in the first 24 hours after liver transplantation.


Eligibility criteria:
inclusion criteria: * older than 18 y * admitted in the icu for a post operative care after liver transplant exclusion criteria: * consent refusal * liver transplant due to acute liver failure * renal transplant ( previous or concomitant) * refusal from the healthcare provider responsible for the patient * renal substitution therapy in the prior 15 days * pregnancy * re-transplant (liver transplant in the previous 6 month) * hepatorenal syndrome current treatment (use of terlipressin + albumin) * refractory and persistent shock during or after transplant
exercise rehabilitation in veteran cancer survivors

Conditions: Cancer

Summary: exercise rehabilitation has the potential as a non-pharmacological approach to reduce persistent neuropathic pain in veterans with lung cancer. by examining the effects of exercise training in veteran cancer survivors with nsclc, there is the potential to revolutionize care for a: common, debilitating, and inadequately treated symptom in a growing population. this could lead to a larger investigation to fill critical gaps in the literature and at the same time help discover a new model of care for veterans with chronic pain. the ultimate goal is to reduce this type of pain for the growing population of cancer survivors while simultaneously reducing the need for problematic opioid management.

persistent or chronic neuropathic pain, either post-thoracotomy persistent pain (ptpp) or chemotherapy-induced peripheral neuropathy (cipn) occurs in a majority of lung cancer patients. thus, not only is this neuropathic pain widespread; there is no way to prevent its development, and long-term use of opioids for control of symptoms could result in addiction. ultimately, ptpp and cipn can lead to long-term suffering and disability during the post-treatment phase.(nsclc), which represents about 85% of lung cancer cases.this is the first project of its kind and the potential impact of this research is large, because exercise training will be a prescription and the first approach for which nsclc survivors can self-manage chronic neuropathic pain. the ultimate goal of the investigators' work is to reduce neuropathic pain for the growing population of cancer survivors while simultaneously reducing the need for problematic pharmacologic management. therefore, results of this study have potential for high impact on symptom care because it will allow effective neuropathic pain treatment to be in full control of the veteran, and likely restore function that is lost during the chronic pain experience. specific aims: 1. to determine the feasibility of conducting an exercise rehabilitation intervention in veterans with nsclc and ptpp or cipn. 2. to determine the effects of a vamhcs-supervised activity rehabilitation program on chronic pain compared to delayed control. 3. to assess changes in fitness, strength, physical function, fatigue, and quality of life (qol) after activity-based rehabilitation compared to control period.

Eligibility criteria:
inclusion criteria: * diagnosis with lung cancer * history of treatment with either thoracotomy procedure or neurotoxic chemotherapy or both * completion of thoracotomy or chemotherapy \> or = 6 months * ability to walk on a treadmill * karnofsky performance status \> 70 * score \> 1 neuropathic pain scale exclusion criteria: * presence of metastatic (stage iv) * life expectancy \< 6 months * musculoskeletal or medical conditions which preclude participation in an exercise program

Keywords: neuropathic pain exercise lung cancer
impact of an app on the quality of life and symptoms in individuals with premenstrual syndrome

Conditions: Premenstrual Syndrome; Premenstrual Syndrome-PMS

Summary: this pilot study explored the effectiveness and acceptance of a digital app for the self-management of pms. a total of 175 participants were randomized into an intervention and a control group. findings indicate that the app offers beneficial effects on pms-specific symptoms and broader health aspects such as fatigue and emotional well-being. the study also provided valuable insights for the design of future larger trials and highlights the promising potential of the app to enhance individualized care.


Eligibility criteria:
inclusion criteria: * legal capacity * residency in germany * female gender * age ≥18 years * diagnosed and medically confirmed current pms (n94.3) * ownership of a smartphone and ability to use it * internet access for app usage and questionnaire completion * email address for registration * willingness to complete questionnaires online * motivation for regular app usage * sufficient proficiency in the german language exclusion criteria: * pregnancy, breastfeeding, or the onset of menopause during the study period * changes in hormonal therapy and/or use of antidepressants within eight weeks prior to the study start and/or planned in the upcoming 12 weeks * previous or current access to the endo-app or other comparable digital health applications, or current active prescription * current participation in other clinical studies * failure to meet the inclusion criteria

Keywords: digital therapeutics premenstrual syndrome (pms)
study of rubitecan in cancer patients with renal or hepatic dysfunction

Conditions: Tumors

Summary: cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.


Eligibility criteria:
inclusion criteria: * the patient is at least 18 years of age. * the patient has histologically or cytologically proven malignancy recurrent or refractory to standard treatment or for which there is no standard therapy. * the patient has measurable disease. * the patient has sufficiently recovered from the acute toxic effects of previous chemotherapy, radiotherapy (no less than 3 weeks prior to randomization), and/or immunotherapy. * the patient's estimated life expectancy is at least 8 weeks. * the patient has a national cancer institute common toxicity criteria (nci ctc) performance status between 0 and 2. * the patient has adequate bone marrow function. * the patient must not have active central nervous system (cns) metastases. exclusion criteria: * the patient has any serious, uncontrolled intercurrent illness or infection. * the patient is receiving anti-retroviral therapy (haart) for hiv infection. * the patient is pregnant or nursing.

Keywords: rubitecan orathecin 9-nitrocamptothecin solid tumors organ dysfunction renal dysfunction hepatic dysfunction rfs 2000